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A B-cell receptor-related gene signature predicts
response to ibrutinib treatment in mantle cell 
lymphoma cell lines
Mantle cell lymphoma (MCL) is a B-cell malignancy
with a broad range of clinical and biological features.
Once all MCL patients were considered to have a poor
prognosis. However, it is now fully established that a
group of MCL patients may experience an indolent dis-
ease without needing treatment for years.1-6 Even among
patients requiring treatment, prognosis is highly hetero-
geneous, with some patients experiencing prolonged
remissions and others suffering rapid relapse. For this rea-
son, there is a critical need for reproducible biomarkers
that can be incorporated into clinical trial design and ulti-
mately used to guide clinical decisions.
We have recently developed a survival predictive
model for patients with advanced MCL aged <65 years,
treated with an intensified induction chemo-immuno
therapeutic regimen followed by high-dose chemothera-
py and autologous stem cell transplantation, in the con-
text of the “Fondazione Italiana Linfomi” (FIL) MCL-0208
phase III randomized clinical trial.7 This model is: 1)
based on the quantitative real-time polymerase chain
reaction (qRT-PCR) values of six representative genes
(AKT3, BCL2, BTK, CD79B, PIK3CD, and SYK); 2) is
applicable both to peripheral blood (PB) MCL cells and to
formalin-fixed paraffin-embedded tissue specimens. It
proved to be an independent predictor of short progres-
sion-free survival (PFS) along with the combined Mantle
Cell Lymphoma International Prognostic Index (MIPI-c)
score. Notably, this 6-gene BCR-related signature was
able to identify a MCL subset with shorter PFS intervals
also in the context of an external independent MCL
cohort,7 again treated with an intensified chemo-
immunotherapy regimen.
Here we analyzed the expression levels of the six genes
of the signature in a number of well-established MCL cell
line models (Rec-1, Jeko-1, Mino, JVM-2, Granta-519,
and Z-138) all bearing the t(11;14)8 by a qRT-PCR
approach identical to that previously reported.7 A hierar-
chical clustering using these values was able to discrimi-
nate between two different groups of MCL cell lines
respectively characterized by a low or high expression of
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Figure 1. Mantle cell lymphoma
(MCL) cell lines and BCR cate-
gories. (A) Quantitative real-time
polymerase chain reaction (qRT-
PCR) analysis of 6-gene signature in
MCL cell lines. Hierarchical cluster-
ing of three BCRlow MCL cell lines
(blue bar under the horizontal den-
drogram) and three BCRhigh MCL cell
lines (red bar under the horizontal
dendrogram), using the six gene
values, is shown. BCRlow and BCRhigh
MCL cell lines were BCRhigh accord-
ing to the Decision Tree (DT) predic-
tion model. Color codes for gene
expression values refer to mean
centered log-ratio values. (B) Gene
expression profile of MCL cell lines.
Hierarchical clustering of three
BCRlow MCL cell lines (blue bar
under the horizontal dendrogram)
and three BCRhighMCL cell lines (red
bar under the horizontal dendro-
gram), using the 2,127 differentially
expressed probes obtained by gene
expression profiling (GEP), is
shown. Color codes for gene expres-
sion values refer to mean centered
log-ratio values. (C) GEP data of
BCRlow and BCRhigh MCL cell lines
were tested for gene set enrich-
ment using gene set enrichment
analysis (GSEA). Reported are the
gene sets found significantly differ-
entially expressed between BCRlow
and BCRhigh MCL cell lines related to
B-cell receptor (BCR) pathway. (Left)
Plot of the enrichment score dis-
playing the main pathway related to
BCR pathway obtained from GSEA.
(Right) Corresponding heat-maps
highlighting the relative expression
of the gene members belonging to
the reported gene sets in BCRlow
(blue bar under the horizontal den-
drogram) and BCRhigh (red bar under
the horizontal dendrogram) MCL
cell lines. Color codes for gene
expression values refer to mean





Figure 2. Anti-IgM stimulation and ibrutinib treatment. (A) Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of 6-gene signature in mantle
cell lymphoma (MCL) cell lines upon soluble anti-IgM stimulation. Hierarchical clustering of three BCRlow MCL cell lines (blue bar under the horizontal dendro-
gram) and three BCRhighMCL cell lines (red bar under the horizontal dendrogram) is shown. (B) qRT-PCR analysis of 6-gene signature in MCL cell lines upon ibru-
tinib treatment. Hierarchical clustering of three BCRlow MCL cell lines (blue bar under the horizontal dendrogram) and three BCRhigh MCL cell lines (red bar under
the horizontal dendrogram) is shown. (C) qRT-PCR analysis of 6-gene signature in MCL cell lines upon soluble anti-IgM stimulation and ibrutinib treatment.
Hierarchical clustering of three BCRlow MCL cell lines (blue bar under the horizontal dendrogram) and three BCRhigh MCL cell lines (red bar under the horizontal
dendrogram), is shown. (D) The histogram plot overlays show (p)-BTK in unstimulated, anti-IgM stimulated, ibrutinib treated and anti-IgM+ibrutinib treated cells
from one representative BCRhigh (Rec-1), and BCRlow (Granta-519) MCL cell lines. (E) qRT-PCR analysis of 6-gene signature in unstimulated MCL primary samples.
Hierarchical clustering of three BCRlow MCL samples (blue bar under the horizontal dendrogram) and six BCRhigh MCL samples (red bar under the horizontal den-
drogram) is shown. (F) qRT-PCR analysis of 6-gene signature in MCL primary samples upon anti-IgM stimulation. Hierarchical clustering of three BCRlowMCL sam-
ples (blue bar under the horizontal dendrogram) and six BCRhigh MCL samples (red bar under the horizontal dendrogram) is shown. (G) Phospho-flow analysis of
(p)-BTK. The histogram plot overlays show (p)-BTK in unstimulated, and anti-IgM stimulated cells from one representative MCL case. (H) Bar chart plot of qRT-
PCR values in nine MCL primary samples upon anti-IgM stimulation. Data represent mean±Standard Error of Mean. P-values refer to paired Student t-test. Color






the six genes, thus recapitulating in these cell lines the
original observation made in primary MCL samples
(Figure 1A).7 By applying the same decision tree (DT)
model previously developed for primary MCL patients,7
the cell lines JVM-2, Granta-519, and Z-138, all with low
expression of the 6-gene signature, were classified as
BCRlow, while the other three cell lines, Rec-1, Jeko-1,
Mino, characterized by higher expression levels of the 6-
gene signature, were classified as BCRhigh, in agreement
with the hierarchical cluster result (Figure 1A). 
To confirm the prediction of the BCR status, as deter-
mined by the application of the DT model, a wider analy-
sis using a global gene expression profiling (GEP)
approach was performed on the same MCL cell lines (fur-
ther details in the Online Supplementary Methods).
Supervised analysis, according to the BCR classification
defined by the DT models, discovered a gene expression
signature composed of 2,127 probes, 1,183 up-regulated
and 944 down-regulated in BCRlow versus BCRhigh MCL cell
lines (Online Supplementary Table S1). A hierarchical clus-
ter, generated using the differentially expressed probes,
was able to correctly split BCRlow MCL cell lines from
BCRhigh MCL cell lines (Figure 1B). Gene set enrichment
analysis (GSEA) highlighted a constitutive overexpression
of genes related to the BCR signaling pathways in the
context of BCRhigh MCL cell lines (Figure 1C), again con-
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Figure 3. Mantle cell lymphoma (MCL) cell lines and ibrutinib sensitivity. Sensitivity of different MCL cell lines to ibrutinib treatment. MCL cell lines were treated
with dimethyl sulfoxide (DMSO) (blue line) or ibrutinib (red line). At the indicated time, the number of viable cell/mL was measured with a trypan blue exclusion
assay. Z-138, JVM-2, Granta-519 were considered insensitive to ibrutinib treatment while Rec-1, Mino, and Jeko-1 were considered to be highly sensitive. Data
represent mean±Standard Error of Mean. P-values refer to one sample t-test. ns: not significant.
firming the results obtained by the DT model. We identi-
fied the presence of TP53 mutations in 4 of 6 cell lines (3
BCRhigh and 1 BCRlow), suggesting that BCR classification
was not related to TP53 mutational status (Online
Supplementary Table S2). These data are in keeping with
findings of the original manuscript7 where, also in the
context of primary MCL samples, no correlation between
BCR classification and TP53 mutational status was
demonstrated (data not shown). On the contrary, while
there was no differential expression of SOX11 between
the BCRhigh and BCRlow primary MCL samples used in our
previous paper,7 in the context of MCL cell line models, a
significant upregulation of SOX11 in BCRhigh cell lines
was observed (Online Supplementary Table S1).
Since the 6-gene signature is related to genes involved
in the BCR engagement, we evaluated the mRNA expres-
sion level changes for these genes in time course experi-
ments at 1 hour (h), 6 h, and 24 h in MCL cell lines after
either stimulation of the BCR by anti-IgM (10 µg/mL), or
inhibition of the BCR pathway by ibrutinib treatment
(100 nM), or a combination of both these approaches
(further details in the Online Supplementary Methods).
After 24 h of stimulus, hierarchical clusters using the
qRT-PCR values of the 6-gene signature clearly differen-
tiated between BCRhigh and BCRlow MCL cell lines (Figure
2A-C), indicating that the expression of these genes rep-
resented an inherent feature of the different cell lines not
influenced by anti-IgM and/or ibrutinib treatment, which
in turn, as expected, modulated BTK phosphorylation
(Figure 2D).9 The same results were obtained using the
earlier (1 h and 6 h) time points (data not shown). In order
to verify whether this phenomenon remained true also in
MCL cells from primary MCL samples, purified MCL
cells from nine samples (3 BCRlow and 6 BCRhigh, accord-
ingly to the DT prediction model) were stimulated for 24
h with anti-IgM. Again, a hierarchical clustering indicated
that the 6-gene signature remained stable upon anti-IgM
stimulation (Figure 2D and E), although inducing the
expected BTK phosphorylation (Figure 2G).9 In agree-
ment with these data, no significant differences were
found between unstimulated and stimulated values
according to Student paired t-test (Figure 2H), again indi-
cating that the mRNA expression levels of the gene of the
6-gene signature were not influenced by external stimuli
such as BCR engagement.
Previous reports demonstrated that the BTK inhibitor
ibrutinib displayed highly selective activity in a subset of
MCL cell lines.8,10 Starting from this observation, we tested
the capability of ibrutinib treatment (100 nM for 7 days)
to impair the proliferation of MCL cell lines. A different
response pattern to that seen with ibrutinib treatment
was observed (Figure 3). In particular, in agreement with
previous reports,8,10 JVM-2, Granta-519, and 
Z-138 cell lines were insensitive to ibrutinib treatment
while the Rec-1, and Jeko-1 were seen to be sensitive, and
Mino had an ‘intermediate’ sensitivity to ibrutinib treat-
ment, showing approximately 50% cell survival at day 7. 
By combining data related to ibrutinib sensitivity and
BCR signature, it was seen that sensitive cell lines (Rec-1,
Jeko-1 and Mino) were those showing higher expression
levels of genes from the 6-gene signature and thus classi-
fied as BCRhigh (Figure 1A), while insensitive cell lines
(JVM-2, Granta-519, and Z-138), by expressing lower
levels of the 6-gene signature, were classified as BCRlow.
We then tested the correlation of BCR signature and ibru-
tinib sensitivity also in six primary MCL samples (3
BCRhigh and 3 BCRlow) (Online Supplementary Figure S1A)
with available PB viable cells. In keeping with the results
reported for MCL cell lines models, BCRhigh cases dis-
played a significant higher sensitivity to ibrutinib treat-
ment with respect to BCRlow samples (Online
Supplementary Figure S1B). When analyzed for the capac-
ity of response to anti-IgM stimulation in terms of BTK
phosphorylation, BCRhigh cases showed greater BTK
phosphorylation with respect to BCRlow cases after anti-
IgM stimulation (Online Supplementary Figure S1C). These
data underline the possibility that BCRhigh samples are
more addicted to BCR stimulation and for this reason
more sensitive to ibrutinib treatment. Further studies are
needed, either on cell lines or on primary MCL cells, to
precisely evaluate the discriminative capacity of the pro-
posed classification method, and/or to alternatively test
the 6-gene signature using approaches of direct amplifica-
tion-free RNA quantification.
Despite high response rates and an improvement in
PFS, current front-line approaches will inevitably fail and
patients will relapse. Moreover, since the treatment
choice at relapse depends on many different factors, in
the era of new BCR inhibitors, one of the preferred
approved therapies includes combination regimens con-
taining the BTK inhibitor ibrutinib, both in the front-line
and relapse settings.3 Despite the relatively high response
rate to single agent ibrutinib in MCL, some patients show
clear responses, while others obtained a modest thera-
peutic benefit.11-13 
Our data underline the clinical significance of the BCR-
related genes in the context of drugs specifically targeting
genes belonging to this pathway. In fact, through the
application of the proposed 6-gene signature, we were
able to identify a MCL subset of cases (labeled as being
BCRhigh) that appeared more addicted to BCR stimulation
with respect to MCL cases with BCRlow profile, thus
explaining the diverse responses of MCL patients to ibru-
tinib, together with other recently reported causes of pri-
mary resistance.8,14 
In conclusion, this newly developed and validated sig-
nature, as well as predicting poor response in the context
of a high-dose chemo-immunotherapy regimen, is associ-
ated with an increased sensitivity of MCL cell lines to
BTK inhibitor exposure. In this regard, given the wider
use of ibrutinib in MCL as first-line at relapse, this signa-
ture could be included and analyzed together with other
recent gene expression-based assays of clinical utility for
MCL15 in future research into risk-adapted therapeutic
strategies in trials testing the new BCR inhibitor mole-
cules.
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